Acrivon Therapeutics, Inc. Common Stock
Stock Forecast, Prediction & Price Target
Acrivon Therapeutics, Inc. Common Stock (ACRV) stock Price Target by analysts
$27
Potential upside: 1915.52%
Acrivon Therapeutics, Inc. Common Stock price prediction
What is Acrivon Therapeutics, Inc. Common Stock stock analysts` prediction?
Acrivon Therapeutics, Inc. Common Stock stock forecast: Based on 1 Wall Street analysts` predicted price targets for Acrivon Therapeutics, Inc. Common Stock in the last 3 months, the avarage price target is $27, with a high forecast of $NaN. The average price target represents a 1915.52% change from the last price of $1.34.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Acrivon Therapeutics, Inc. Common Stock stock Price Target by analysts
Full breakdown of analysts given Acrivon Therapeutics, Inc. Common Stock price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Etzer Darout BMO Capital | 0% 0/3 | 11 months ago | $27 1915.52% upside | $7.92 | StreetInsider | Previous targets (2) |
Etzer Darout BMO Capital | 0% 0/3 | about 1 year ago | $28 1990.17% upside | $8.91 | TheFly | Previous targets (2) |
Matthew Biegler Oppenheimer | 0% 0/2 | about 1 year ago | $18 1243.68% upside | $7.26 | TheFly | Previous targets (1) |
Etzer Darout BMO Capital | 0% 0/3 | over 1 year ago | $25 1766.22% upside | $8.51 | StreetInsider | Previous targets (2) |
Emily Bodnar H.C. Wainwright | 0% 0/2 | over 1 year ago | $22 1542.28% upside | $8.35 | TheFly | Previous targets (1) |
Matthew Biegler Oppenheimer | 0% 0/2 | over 1 year ago | $21 1467.63% upside | $8.36 | StreetInsider | Previous targets (1) |
Silvan Tuerkcan JMP Securities | 0% 0/1 | over 1 year ago | $17 1169.03% upside | $9.5 | TheFly | Previous targets (0) |
Joseph Catanzaro Piper Sandler | 0% 0/2 | over 1 year ago | $30 2139.47% upside | $9.2 | StreetInsider | Previous targets (1) |
Emily Bodnar H.C. Wainwright | 0% 0/2 | over 1 year ago | $20 1392.98% upside | $7.19 | StreetInsider | Previous targets (1) |
Unknown Jefferies | N/A | almost 3 years ago | $17 1169.03% upside | $12.5 | Benzinga | N/A |
Joseph Catanzaro Piper Sandler | 0% 0/2 | almost 3 years ago | $25 1766.22% upside | $12.5 | TheFly | Previous targets (1) |
Acrivon Therapeutics, Inc. Common Stock Financial Estimates
Acrivon Therapeutics, Inc. Common Stock Revenue Estimates
Acrivon Therapeutics, Inc. Common Stock EBITDA Estimates
Acrivon Therapeutics, Inc. Common Stock Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $1.00M Low: $1.00M High: $1.00M avg. 0% | Avg: $20.70M Low: $20.70M High: $20.70M avg. 1952.01% | Avg: $84.93M Low: $84.93M High: $84.93M avg. 310.16% | Avg: $173.39M Low: $173.39M High: $173.39M avg. 104.14% |
Net Income
% change YoY
| $-16.24M N/A | $-29.67M -82.70% | $-60.38M -103.48% | Avg: $-96.22M Low: $-69.32M High: $-39.74M avg. -59.35% | Avg: $-105.66M Low: $-89.85M High: $-30.90M avg. -9.80% | Avg: $-48.46M Low: $-48.46M High: $-48.46M avg. 54.13% | Avg: $-21.01M Low: $-21.01M High: $-21.01M avg. 56.62% |
EBITDA
% change YoY
| $-16.14M N/A | $-32.65M -102.24% | $-59.85M -83.27% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
EPS
% change YoY
| -$0.78 N/A | -$1.35 -73.07% | -$2.74 -102.96% | Avg: -$2.49 Low: -$3.14 High: -$1.8 avg. 9.00% | Avg: -$2.53 Low: -$4.07 High: -$1.4 avg. -1.52% | Avg: -$2.2 Low: -$2.2 High: -$2.2 avg. 13.28% | Avg: -$0.95 Low: -$0.95 High: -$0.95 avg. 56.62% |
Operating Expenses
% change YoY
| $16.18M N/A | $32.65M 101.78% | $66.70M 104.24% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is Acrivon Therapeutics, Inc. Common Stock stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 10.40% in 2025-2028.
We have gathered data from 7 analysts. Their low estimate is -69.32M, average is -96.22M and high is -39.74M.
What is Acrivon Therapeutics, Inc. Common Stock stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 591.57% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $1.00M, average is $1.00M and high is $1.00M.
What is Acrivon Therapeutics, Inc. Common Stock stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 19.34% in 2025-2028.
We have gathered data from 7 analysts. Their low earnings per share estimate is -$3.14, average is -$2.49 and high is $-1.8.
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Acrivon Therapeutics, Inc. Common Stock stock. The most successful analyst is Etzer Darout.